$29.3 M

FCSC Mkt cap, 12-Dec-2019

$1 M

Fibrocell Science Revenue Q3, 2019
Fibrocell Science Gross profit (Q3, 2019)-667 K
Fibrocell Science Gross profit margin (Q3, 2019), %(65.5%)
Fibrocell Science Net income (Q3, 2019)-7.2 M
Fibrocell Science EBIT (Q3, 2019)-4.4 M
Fibrocell Science Cash, 30-Sept-20196.8 M
Fibrocell Science EV27.5 M

Fibrocell Science Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

153.0k200.0k180.0k492.0k355.0k

Revenue growth, %

(10%)173%(28%)

Cost of goods sold

8.4m8.1m2.3m722.0k697.0k

Gross profit

(8.2m)(7.9m)(2.1m)(230.0k)(342.0k)

Gross profit Margin, %

(5361%)(3926%)(1184%)(47%)(96%)

Sales and marketing expense

2.2m

R&D expense

9.0m12.6m16.2m10.0m8.4m6.5m6.0m

General and administrative expense

12.2m10.1m11.6m11.3m9.8m6.7m6.4m

Operating expense total

21.2m22.7m27.8m37.2m26.1m19.0m12.4m

Depreciation and amortization

200.0k

EBIT

(29.4m)(30.5m)(30.0m)(37.4m)(26.5m)(19.0m)(12.4m)

EBIT margin, %

(19209%)(15251%)(16641%)(7603%)(7459%)

Interest expense

1.0m6.0k8.0k56.0k300.0k

Interest income

368.0k17.0k

Pre tax profit

(26.1m)(30.6m)(25.6m)(34.5m)(15.3m)(16.2m)(10.3m)

Income tax expense

(2.5m)

Net Income

(23.2m)(30.6m)(25.6m)(34.5m)(15.3m)(16.2m)(10.3m)

Quarterly

USDQ2, 2011Q3, 2011Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

253.3k159.4k69.0k26.0k62.0k68.0k46.0k58.0k20.0k194.0k137.0k79.0k16.0k87.0k215.0k21.8m1.0m

Cost of goods sold

125.8k96.6k2.3m2.4m2.2m1.9m793.0k547.0k512.0k147.0k162.0k204.0k18.0k392.0k287.0k5.2m1.7m

Gross profit

127.5k62.8k(2.3m)(2.3m)(2.2m)(1.9m)(747.0k)(489.0k)(492.0k)47.0k(25.0k)(125.0k)(2.0k)(305.0k)(72.0k)16.6m(667.0k)

Gross profit Margin, %

50%39%(3264%)(8942%)(3516%)(2738%)(1624%)(843%)(2460%)24%(18%)(158%)(12%)(351%)(33%)76%(65%)

R&D expense

1.6m1.9m426.0k1.2m1.2m8.4m7.4m2.6m2.9m4.0m3.7m4.2m2.6m2.4m1.6m1.5m1.7m1.7m1.6m1.4m1.9m600.0k763.0k

General and administrative expense

3.3m3.9m2.6m2.4m2.5m2.9m2.8m3.5m2.8m2.9m3.6m2.5m2.7m2.5m2.7m1.5m1.7m2.0m1.6m1.6m1.9m2.5m2.9m

Operating expense total

4.9m5.8m3.1m3.6m3.6m11.3m10.3m6.1m5.7m6.9m7.3m6.7m6.7m10.0m4.9m4.5m5.0m4.6m3.0m3.1m3.9m3.1m3.7m

EBIT

(4.7m)(5.8m)(5.3m)(5.9m)(5.8m)(13.1m)(11.0m)(6.6m)(6.2m)(6.9m)(7.4m)(6.8m)(6.7m)(10.3m)(5.0m)(4.5m)(5.0m)(4.6m)(3.0m)(3.1m)(3.9m)13.6m(4.4m)

EBIT margin, %

(1871%)(3608%)(7696%)(22708%)(9377%)(19296%)(23913%)(11372%)(30955%)(3538%)(5372%)(8637%)(41675%)(11861%)(2333%)62%(428%)

Interest expense

283.7k265.0k140.0k2.0k1.0k1.0k4.0k4.0k12.0k18.0k27.0k98.0k41.0k362.0k110.0k43.0k

Interest income

40.0k1.0k2.0k

Pre tax profit

11.0m(5.8m)(6.2m)(12.9m)(14.0m)(2.3m)(6.0m)(8.5m)(6.8m)(1.5m)(1.4m)(8.1m)(2.3m)(5.0m)(14.0m)(115.0k)(2.9m)(2.9m)(3.7m)12.4m(7.9m)

Income tax expense

(54.0k)634.0k(700.0k)

Net Income

(10.1m)6.9m11.5m(5.8m)(6.2m)(12.9m)(14.0m)(2.3m)(6.0m)(8.5m)(6.8m)(1.5m)(1.4m)(8.1m)(2.3m)(5.0m)(14.0m)(115.0k)(2.9m)(2.9m)(3.7m)11.7m(7.2m)

Fibrocell Science Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

10.8m31.3m60.0m37.5m29.3m17.5m17.4m14.4m

Accounts Receivable

215.7k62.0k28.0k4.0k

Prepaid Expenses

1.2m1.3m1.2m1.3m1.2m485.0k105.0k

Inventories

266.3k477.0k597.0k571.0k482.0k

Current Assets

12.5m33.2m61.9m39.3m31.0m18.0m17.9m14.5m

PP&E

1.4m1.7m1.7m1.6m1.6m1.5m1.5m1.2m

Total Assets

20.3m40.6m69.0m45.6m36.7m19.6m19.4m15.8m

Accounts Payable

1.9m921.0k3.0m1.1m499.0k440.0k862.0k452.0k

Short-term debt

6.7m1.1m1.7m2.2m

Current Liabilities

9.6m1.6m3.6m3.5m15.4m3.0m4.4m2.2m

Long-term debt

Total Debt

6.7m1.7m

Total Liabilities

25.9m2.3m4.3m15.2m22.5m11.7m10.4m6.2m

Common Stock

95.7k656.0k40.0k41.0k44.0k26.0k10.0k

Preferred Stock

Additional Paid-in Capital

43.7m111.8m167.3m143.1m161.3m170.4m187.8m198.6m

Retained Earnings

(102.7m)(112.7m)(147.2m)(162.6m)(178.8m)(189.1m)

Total Equity

(5.6m)38.3m64.7m30.4m14.2m7.9m9.0m9.6m

Debt to Equity Ratio

-1.2 x0.1 x

Debt to Assets Ratio

0.3 x0 x

Financial Leverage

-3.6 x1.1 x1.1 x1.5 x2.6 x2.5 x2.2 x1.6 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

2.6m14.8m4.2m2.6m118.0k26.2m20.8m16.9m54.0m49.5m44.2m33.3m26.9m36.9m13.1m8.2m21.3m20.6m15.9m11.9m12.2m15.4m16.1m11.3m13.7m6.8m

Accounts Receivable

238.5k234.4k242.4k26.0k72.0k45.0k58.0k14.0k2.0k3.0k3.0k294.0k1.9m2.5m

Prepaid Expenses

357.6k1.4m993.8k1.1m734.0k1.4m885.0k706.0k480.0k1.1m730.0k467.0k1.0m636.0k374.0k564.0k441.0k265.0k497.0k455.0k294.0k923.0k841.0k1.3m

Inventories

266.7k315.9k604.5k307.1k306.0k477.0k621.0k574.0k506.0k476.0k610.0k544.0k484.0k566.0k475.0k109.0k

Current Assets

3.5m16.8m6.0m27.8m22.2m19.2m55.5m50.7m45.3m34.9m28.1m38.0m14.6m8.9m21.7m21.1m16.4m12.2m12.7m15.9m16.4m12.5m24.9m18.7m

PP&E

709.5k732.3k1.6m1.7m1.6m1.5m1.7m1.7m1.7m1.7m1.6m1.7m1.6m1.5m1.5m1.5m1.5m1.5m1.4m1.4m1.3m1.2m1.3m1.4m

Total Assets

10.5m23.8m13.8m35.1m29.4m26.3m62.4m57.4m51.9m41.2m34.1m43.9m20.2m10.5m23.2m22.7m18.0m13.8m14.1m17.3m17.7m18.1m34.9m27.8m

Accounts Payable

770.2k1.1m955.8k1.2m1.1m1.2m903.0k1.4m1.1m1.9m2.0m2.6m893.0k553.0k361.0k566.0k658.0k601.0k508.0k635.0k782.0k1.5m1.1m1.6m

Short-term debt

7.9m6.4m6.9m2.7m1.2m1.4m1.5m1.8m1.9m2.1m2.3m

Current Liabilities

10.4m8.9m8.9m1.7m1.7m2.6m2.4m3.2m3.6m6.0m5.2m5.3m3.4m3.1m2.5m3.0m3.4m3.5m1.9m2.0m1.8m3.5m7.1m3.7m

Long-term debt

873.1k5.1m5.1m5.0m

Total Debt

7.9m6.4m6.9m3.6m1.2m1.4m1.5m1.8m1.9m2.1m2.3m5.1m5.1m5.0m

Total Liabilities

37.2m20.1m25.5m2.5m2.8m3.3m21.3m18.1m18.3m18.9m17.7m12.6m6.9m4.7m12.2m12.2m21.4m17.1m7.9m7.9m7.5m12.1m17.0m17.1m

Common Stock

45.5k95.3k96.1k15.0m30.0m26.0k26.0k28.0k41.0k41.0k41.0k41.0k41.0k44.0k44.0k44.0k44.0k15.0k15.0k15.0k28.0k8.0k9.0k10.0k10.0k10.0k

Preferred Stock

Additional Paid-in Capital

17.6m43.4m44.1m112.6m112.6m120.0m142.2m142.6m142.9m143.5m144.4m160.8m162.0m162.6m170.1m178.0m178.1m178.4m187.9m194.0m197.6m198.7m198.9m198.9m

Retained Earnings

(101.1m)(103.3m)(109.3m)(121.2m)(128.0m)(129.5m)(148.7m)(156.8m)(159.1m)(167.6m)(181.6m)(181.7m)(181.7m)(184.6m)(187.5m)(192.7m)(181.0m)(188.2m)

Total Equity

(27.1m)3.7m(11.7m)(8.4m)32.7m26.5m23.0m41.1m39.3m33.5m22.3m16.4m31.4m13.3m5.8m11.0m10.5m(3.4m)(3.3m)6.3m9.4m10.2m6.0m17.9m10.7m

Debt to Equity Ratio

-0.3 x1.7 x-0.6 x0 x0 x0 x0.1 x0.1 x0.1 x0.2 x0.9 x0.3 x

Debt to Assets Ratio

0.7 x0.3 x0.5 x0 x0 x0 x0 x0.1 x0 x0.1 x0.3 x0.1 x

Financial Leverage

-0.4 x6.5 x-1.2 x1.1 x1.1 x1.1 x1.5 x1.5 x1.5 x1.8 x2.1 x1.4 x1.5 x1.8 x2.1 x2.2 x-5.2 x-4.1 x2.3 x1.8 x1.7 x3 x2 x2.6 x

Fibrocell Science Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(23.2m)(30.6m)(25.6m)(34.5m)(15.3m)(16.2m)(10.3m)

Depreciation and Amortization

821.0k863.0k883.0k767.0k564.0k384.0k392.0k

Accounts Receivable

(60.0k)54.0k12.0k9.0k12.0k

Inventories

(477.0k)(120.0k)26.0k89.0k126.0k

Accounts Payable

(966.0k)2.0m(1.8m)(114.0k)(139.0k)69.0k(24.0k)

Cash From Operating Activities

(22.6m)(20.1m)(22.3m)(24.1m)(29.4m)(17.0m)(12.7m)

Purchases of PP&E

(493.0k)(360.0k)(242.0k)(271.0k)(253.0k)(433.0k)(164.0k)

Cash From Investing Activities

509.0k(360.0k)(242.0k)(245.0k)(252.0k)(433.0k)(164.0k)

Long-term Borrowings

(3.0k)(2.0k)

Dividends Paid

(470.0k)

Cash From Financing Activities

42.6m49.1m16.1m17.9m17.4m9.9m

Net Change in Cash

20.5m28.7m(22.5m)(8.2m)(11.8m)(98.0k)(3.0m)

Interest Paid

1.9m

Income Taxes Paid

Quarterly

USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(4.0m)(5.8m)(12.0m)(25.0m)(14.0m)(16.3m)(22.3m)(8.5m)(15.3m)(16.8m)(1.4m)(9.5m)(11.8m)(5.0m)(19.0m)(19.1m)(2.9m)(8.7m)(3.7m)8.1m873.0k

Depreciation and Amortization

265.7k604.0k226.0k456.0k693.0k222.0k452.0k673.0k140.0k346.0k554.0k217.0k391.0k476.0k91.0k184.0k282.0k101.0k202.0k302.0k85.0k168.0k251.0k

Accounts Receivable

(82.0k)45.0k(10.0k)23.0k(35.0k)(2.0k)11.0k1.0k2.0k9.0k10.0k12.0k12.0k(1.9m)(2.5m)

Inventories

(306.0k)(144.0k)(97.0k)91.0k121.0k(13.0k)27.0k87.0k5.0k7.0k222.0k482.0k

Accounts Payable

(186.0k)324.0k221.0k248.0k(2.1m)(1.6m)(1.9m)774.0k833.0k1.5m338.0k(3.0k)(212.0k)(55.0k)192.0k132.0k23.0k51.0k258.0k1.1m485.0k1.1m

Cash From Operating Activities

(15.3m)(5.1m)(10.4m)(16.0m)(6.0m)(10.3m)(15.5m)(4.2m)(10.8m)(16.5m)(16.1m)(20.9m)(25.6m)(4.8m)(9.0m)(12.9m)(4.8m)(7.5m)(10.2m)(3.1m)(646.0k)(7.3m)

Purchases of PP&E

(473.0k)(100.0k)(122.0k)(162.0k)(79.0k)(211.0k)(307.0k)(108.0k)(111.0k)(208.0k)(58.0k)(143.0k)(187.0k)(87.0k)(243.0k)(348.0k)(35.0k)(83.0k)(155.0k)(9.0k)(87.0k)(340.0k)

Cash From Investing Activities

529.0k(100.0k)(122.0k)(162.0k)(79.0k)(211.0k)(307.0k)(108.0k)(111.0k)(208.0k)(58.0k)(143.0k)(186.0k)(87.0k)(243.0k)(348.0k)(35.0k)(83.0k)(155.0k)(9.0k)(87.0k)(340.0k)

Long-term Borrowings

(2.0k)(3.0k)(2.0k)(2.0k)(2.0k)

Dividends Paid

(157.0k)

Cash From Financing Activities

4.0m4.0k1.7m152.0k253.0k16.1m(52.0k)(111.0k)17.8m7.9m7.6m7.6m(420.0k)5.6m9.1m(22.0k)(22.0k)(37.0k)

Net Change in Cash

(10.7m)(5.2m)(10.5m)(14.5m)(6.0m)(10.5m)(15.8m)(4.2m)(10.6m)(564.0k)(16.2m)(21.1m)(8.0m)3.0m(1.6m)(5.6m)(5.2m)(2.0m)(1.3m)(3.1m)(755.0k)(7.7m)

Interest Paid

1.2m

Fibrocell Science Ratios

USDQ2, 2011

Debt/Equity

-0.3 x

Debt/Assets

0.7 x

Financial Leverage

-0.4 x